Lexington, MA, May 25, 2023 –(PR.com)– Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, today announced that physicians in Italy have initiated enrollment of chronically transfused patients with beta thalassemia to receive transfusions using red blood cells (RBCs) processed and stored with the Hemanext ONE® system. Hemanext expects these transfusions, which are part of a post-CE mark clinical study in Genoa, Italy, to begin in June.

The study in Genoa is a single center, prospective, historical control study designed to assess the safety and efficacy of transfusing hypoxic RBCs in beta thalassemia patients undergoing chronic transfusions. Efficacy in this case is defined as a reduction in volume of RBCs transfused. Additional endpoints such as mean change in hemoglobin and hematocrit, quality of life (QoL), serum ferritin (during first 12 months), and the impact of hypoxic RBCs on iron…